Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Moderator

Melinda Gooderham, MD, MSc, FRCP

Assistant Professor
Queens University
Medical Director
SKiN Centre for Dermatology
Peterborough, Ontario, Canada

Disclosures

Melinda Gooderham, MD, MSc, FRCP, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Akros Pharma Inc.; Amgen, Inc.; AnaptysBio, Inc.; Arcutis Biotherapeutics, Inc.; Aristea Therapeutics; Asana BioSciences, LLC; Aslan Pharmaceuticals; Bausch Health Companies Inc.; Boehringer Ingelheim International GmbH; Celgene Corporation; Eli Lilly and Company; Galderma Laboratories, L.P.; Janssen, Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; LEO Pharma, Inc.; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceuticals Industries, Ltd. UCB Pharma, Inc.
Speaker or member of speakers bureau for: AbbVie, Inc.; Amgen; Arcutis Biotherapeutics, Inc.; Aslan Pharmaceuticals; Bausch Health Companies Inc.; Boehringer Ingelheim International GmbH; Celgene Corporation; Eli Lilly and Company; Galderma SA; Janssen, Inc.; LEO Pharma, Inc.; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; UCB Pharma, Inc.
Research funding from: AbbVie, Inc.; Akros Pharma Inc.; Amgen, Inc.; AnaptysBio, Inc.; Arcutis Biotherapeutics, Inc.; Aristea Therapeutics; Aslan Pharmaceuticals; Bausch Health Companies Inc.; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Celgene Corporation; Coherus Biosciences; Dermira Inc.; Eli Lilly and Company; Galderma SA; GlaxoSmithKline; Incyte Corporation; Janssen, Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; LEO Pharma, Inc.; MedImmune Inc.; Merck and Co.; MoonLake Immunotherapeutics; Nimbus Therapeutics; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; UCB Pharma, Inc.

Faculty

Laura Coates, MD, PhD

Associate Professor
University of Oxford
Oxford, United Kingdom

Disclosures

Laura Coates, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Amgen, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Galapagos; Gilead Sciences, Inc.; Janssen; MoonLake Immunotherapeutics; Novartis; Pfizer, Inc.; UCB Pharma, Inc.
Speaker or member of speakers bureau for: AbbVie, Inc.; Amgen, Inc.; Biogen; Celgene Corporation; Eli Lilly and Company; Galapagos; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen; Medac Pharma, Inc.; Novartis; Pfizer, Inc.; UCB Pharma, Inc.
Research funding from: AbbVie, Inc.; Amgen, Inc.; Celgene Corporation; Eli Lilly and Company; Janssen; Novartis; Pfizer, Inc.; UCB Pharma, Inc.

Mark G. Lebwohl, MD

Dean for Clinical Therapeutics
Chairman Emeritus
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York, United States

Disclosures

Mark G. Lebwohl, MD, has the following relevant financial relationships:
Consultant or advisor for: AnaptysBio, Inc.; Arcutis Biotherapeutics, Inc.; Arena Pharmaceuticals, Inc.; Aristea Therapeutics; Avotres Therapeutics; BioMX; Boehringer Ingelheim Pharmaceuticals, Inc.; Brickell Biotech; Castle Biosciences; Corevitas; Dermavant Sciences, Inc.; Evommune, Inc.; Forte Biosciences; Hexima Ltd.; Meiji Seika Kaisha, Ltd.; Mindera; Pfizer, Inc.; Seanergy; Verrica Pharmaceuticals; Vial
Research funding from: AbbVie, Inc.; Amgen, Inc.; Arcutis Biotherapeutics, Inc.; Avotres Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Cara Therapeutics; Dermavant Sciences, Inc.; Incyte Corporation; Inozyme; Janssen Research & Development LLC; Lilly USA, LLC; Novartis; Ortho Dermatologics; Regeneron; UCB Pharma, Inc.

Editors

Marinella Calle, PhD, CMPP

Senior Medical Education Director, WebMD Global, LLC

Disclosures

Marinella Calle, PhD, CMPP, has no relevant financial relationships.

Diana Lucifero, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Diana Lucifero, PhD, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC

Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease?

Authors: Melinda Gooderham, MD, MSc, FRCP; Laura Coates, MD, PhD; Mark G. Lebwohl, MD
CME / ABIM MOC Released: 1/3/2023
Valid for credit through: 1/3/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 0.75 ABIM MOC points

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for dermatologists, rheumatologists, and primary care physicians.

The goal of this activity is for learners to be better able to relate the most recent data on psoriasis and PsA from recent conferences to their clinical practice.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical data on emerging interleukin-17 (IL-17) inhibitors in psoriatic disease
- Clinical data relating to disease biology
Demonstrate greater confidence in their ability to
- Optimize care for patients with psoriatic disease

Disclosures

Disclosures for additional planners can be found here.

Moderator

Melinda Gooderham, MD, MSc, FRCP

Assistant Professor
Queens University
Medical Director
SKiN Centre for Dermatology
Peterborough, Ontario, Canada

Disclosures

Melinda Gooderham, MD, MSc, FRCP, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Akros Pharma Inc.; Amgen, Inc.; AnaptysBio, Inc.; Arcutis Biotherapeutics, Inc.; Aristea Therapeutics; Asana BioSciences, LLC; Aslan Pharmaceuticals; Bausch Health Companies Inc.; Boehringer Ingelheim International GmbH; Celgene Corporation; Eli Lilly and Company; Galderma Laboratories, L.P.; Janssen, Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; LEO Pharma, Inc.; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceuticals Industries, Ltd. UCB Pharma, Inc.
Speaker or member of speakers bureau for: AbbVie, Inc.; Amgen; Arcutis Biotherapeutics, Inc.; Aslan Pharmaceuticals; Bausch Health Companies Inc.; Boehringer Ingelheim International GmbH; Celgene Corporation; Eli Lilly and Company; Galderma SA; Janssen, Inc.; LEO Pharma, Inc.; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; UCB Pharma, Inc.
Research funding from: AbbVie, Inc.; Akros Pharma Inc.; Amgen, Inc.; AnaptysBio, Inc.; Arcutis Biotherapeutics, Inc.; Aristea Therapeutics; Aslan Pharmaceuticals; Bausch Health Companies Inc.; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Celgene Corporation; Coherus Biosciences; Dermira Inc.; Eli Lilly and Company; Galderma SA; GlaxoSmithKline; Incyte Corporation; Janssen, Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; LEO Pharma, Inc.; MedImmune Inc.; Merck and Co.; MoonLake Immunotherapeutics; Nimbus Therapeutics; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; UCB Pharma, Inc.

Faculty

Laura Coates, MD, PhD

Associate Professor
University of Oxford
Oxford, United Kingdom

Disclosures

Laura Coates, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Amgen, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Galapagos; Gilead Sciences, Inc.; Janssen; MoonLake Immunotherapeutics; Novartis; Pfizer, Inc.; UCB Pharma, Inc.
Speaker or member of speakers bureau for: AbbVie, Inc.; Amgen, Inc.; Biogen; Celgene Corporation; Eli Lilly and Company; Galapagos; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen; Medac Pharma, Inc.; Novartis; Pfizer, Inc.; UCB Pharma, Inc.
Research funding from: AbbVie, Inc.; Amgen, Inc.; Celgene Corporation; Eli Lilly and Company; Janssen; Novartis; Pfizer, Inc.; UCB Pharma, Inc.

Mark G. Lebwohl, MD

Dean for Clinical Therapeutics
Chairman Emeritus
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York, United States

Disclosures

Mark G. Lebwohl, MD, has the following relevant financial relationships:
Consultant or advisor for: AnaptysBio, Inc.; Arcutis Biotherapeutics, Inc.; Arena Pharmaceuticals, Inc.; Aristea Therapeutics; Avotres Therapeutics; BioMX; Boehringer Ingelheim Pharmaceuticals, Inc.; Brickell Biotech; Castle Biosciences; Corevitas; Dermavant Sciences, Inc.; Evommune, Inc.; Forte Biosciences; Hexima Ltd.; Meiji Seika Kaisha, Ltd.; Mindera; Pfizer, Inc.; Seanergy; Verrica Pharmaceuticals; Vial
Research funding from: AbbVie, Inc.; Amgen, Inc.; Arcutis Biotherapeutics, Inc.; Avotres Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Cara Therapeutics; Dermavant Sciences, Inc.; Incyte Corporation; Inozyme; Janssen Research & Development LLC; Lilly USA, LLC; Novartis; Ortho Dermatologics; Regeneron; UCB Pharma, Inc.

Editors

Marinella Calle, PhD, CMPP

Senior Medical Education Director, WebMD Global, LLC

Disclosures

Marinella Calle, PhD, CMPP, has no relevant financial relationships.

Diana Lucifero, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Diana Lucifero, PhD, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education

CME / ABIM MOC

Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease?

Authors: Melinda Gooderham, MD, MSc, FRCP; Laura Coates, MD, PhD; Mark G. Lebwohl, MDFaculty and Disclosures

CME / ABIM MOC Released: 1/3/2023

Valid for credit through: 1/3/2024, 11:59 PM EST

processing....

Deutscher Expertenkommentar

Dieser Kommentar ist Teil einer umfangreicheren Fortbildungsmaßnahme. Kehren Sie für den Zugriff auf alle zugehörigen Fortbildungsinhalte nach Ihrer Teilnahme bitte zurück zu Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease? .

« Return to: Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease?

Download Slides

Activity Transcript

Expert Commentary

Print
Like Tweet

Faculty and Disclosures

Moderator

Melinda Gooderham, MD, MSc, FRCP

Faculty

Laura Coates, MD, PhD

Mark G. Lebwohl, MD

Editors

Marinella Calle, PhD, CMPP

Diana Lucifero, PhD

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC

Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease?

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Moderator

Melinda Gooderham, MD, MSc, FRCP

Faculty

Laura Coates, MD, PhD

Mark G. Lebwohl, MD

Editors

Marinella Calle, PhD, CMPP

Diana Lucifero, PhD

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease?

Deutscher Expertenkommentar

Expert Commentary